Healthy China

Interpretation of the National Action Plan for Eliminating Hepatitis C as a Public Health Threat (2021–2030) 627

Preplanned Studies

Identifying the Optimal Age for Herpes Zoster Vaccination — Yichang City, Hubei Province, China, 2017–2019 631

Characteristics and Associated Factors of E-cigarette Use Among Secondary School Students — 6 PLADs in China, 2021 635

Prevalence of Metabolic Syndrome and Risk Factors Among Chinese Adults: Results from a Population-Based Study — Beijing, China, 2017–2018 640

Notifiable Infectious Diseases Reports

Reported Cases and Deaths of National Notifiable Infectious Diseases — China, May 2022 646
Editorial Board

Editor-in-Chief
George F. Gao
Deputy Editor-in-Chief
Liming Li, Gabriel M Leung, Zijian Feng
Executive Editor
Feng Tan

Members of the Editorial Board

Xiangsheng Chen  Xiaoyou Chen  Zhuo Chen (USA)  Xianbin Cong
Gangqiang Ding  Xiaoping Dong  Mengjie Han  Guangxue He
Zhongwei Jia  Xi Xin  Biao Kan  Haidong Kan
Qun Li  Tao Li  Zhongjie Li  Min Liu
Qiyong Liu  Jinxing Lu  Huiming Luo  Huihai Ma
Jiaqi Ma  Jun Ma  Ron Moolenaar (USA)  Daxin Ni
Lance Rodewald (USA)  RJ Simonds (USA)  Ruitai Shao  Yiming Shao
Xiaoming Shi  Yuelong Shu  Xu Su  Chengye Sun
Dianjun Sun  Hongqiang Sun  Quanfu Sun  Xin Sun
Jinling Tang  Kanglin Wan  Huaping Wang  Linhong Wang
Guizhen Wu  Jing Wu  Weiping Wu  Xifeng Wu (USA)
Yongning Wu  Zunyou Wu  Lin Xiao  Fuji X (USA)
Wenbo Xu  Hong Yan  Hongyan Yao  Zundong Yin
Hongjie Yu  Shicheng Yu  Xuejie Yu (USA)  Jianzhong Zhang
Liubo Zhang  Rong Zhang  Tiemei Zhang  Wenhua Zhao
Yanlin Zhao  Xiaoying Zheng  Zhijie Zheng (USA)  Maigeng Zhou

Advisory Board

Director of the Advisory Board
Jiang Lu
Vice-Director of the Advisory Board
Yu Wang, Jianjun Liu, Jun Yan

Members of the Advisory Board

Chen Fu  Gauden Galea (Malta)  Dongfeng Gu  Qing Gu
Yan Guo  Ailan Li  Jiafa Liu  Peilong Liu
Yuanli Liu  Kai Lu  Roberta Ness (USA)  Guang Ning
Minghui Ren  Chen Wang  Hua Wang  Kean Wang
Xiaoqi Wang  Zijun Wang  Fan Wu  Xianping Wu
Jingjing Xi  Jianguo Xu  Gonghuan Yang  Tilahun Yilma (USA)
Guang Zeng  Xiaopeng Zeng  Yonghui Zhang  Bin Zou

Editorial Office

Directing Editor
Feng Tan
Managing Editors
Lijie Zhang, Yu Chen, Peter Hao (USA)
Senior Scientific Editors
Ning Wang, Ruotao Wang, Shicheng Yu, Qian Zhu
Scientific Editors
Weihong Chen, Xudong Li, Nankun Liu, Liuying Tang
Xi Xu, Qing Yue, Ying Zhang
Interpretation of the National Action Plan for Eliminating Hepatitis C as a Public Health Threat (2021–2030)

Jian Li; Lin Pang; Zhongfu Liu

Summary
Hepatitis C virus (HCV) infection is a major public health problem in China. In 2016, the World Health Organization (WHO) proposed a goal to eliminate viral hepatitis as a public health threat by 2030, and in 2018, the National Health Commission of China launched Hepatitis C Elimination Action by 2030. Hepatitis C control and prevention has made significant progress in China in recent years. To implement the “Healthy China 2030” plan and the Healthy China Initiative (2019–2030), and to contribute to the global target of eliminating viral hepatitis as a public health threat by 2030, the National Health Commission of China and eight other government departments jointly issued the National Action Plan for Eliminating Hepatitis C as a Public Health Threat (2021–2030) (hereinafter referred to as the “National Plan”) in 2021. The National Plan has an overarching goal and 15 specific targets that cover health education, comprehensive prevention interventions, testing and treatment, and capacity building. The National Plan introduces key tasks and strategies of “five strengthenings, one expanding, and one implementation,” i.e., strengthening health education, comprehensive prevention, referral and treatment, drug supply, and information management; expanding testing; and implementing relevant medical insurance policies. The National Plan also proposes key guaranteeing measures of “four intensifications and one mobilization,” i.e., intensification of organizational leadership, capacity building, scientific research and international cooperation, and supervision and fulfillment; mobilization of social participation. The National Plan is an important component of the Healthy China initiative, adhering to the integration of treatment and prevention and deepening the “integration of medical treatment, medical insurance, and medicine supplies.” In this review, we describe the National Plan and discuss its challenges and prospects.

BACKGROUND
Hepatitis C is a global public health problem. The World Health Organization (WHO) estimated that in 2019, approximately 58 million people were living with chronic hepatitis C virus infection and 290 thousand people died from hepatitis C worldwide (1). Hepatitis C is a major infectious disease that impacts China. The Law of the People’s Republic of China on the Prevention and Control of Infectious Diseases designates hepatitis C a Class B infectious disease (2). In recent years, approximately 200 thousand hepatitis C cases have been newly reported each year. Approximately 7.6 million people have been infected by hepatitis C virus (HCV) in China, and 4.56 million people are currently living with chronic HCV infection. Hepatitis C infection causes a large disease burden and can lead to liver cirrhosis and hepatocellular carcinoma (HCC) without timely diagnosis and treatment.

In 2016, WHO proposed a goal to eliminate viral hepatitis as a public health threat by 2030 (3). In 2018, the National Health Commission of China launched the Hepatitis C Elimination Action by 2030. The document, “China Viral Hepatitis Prevention and Control Program (2017–2020)” was issued in 2017, and the program has been conscientiously implemented ever since (4). Significant progress has been made in terms of publicity and education, comprehensive interventions, testing and diagnosis, standardized treatment, direct-acting antiviral agent (DAA) development and registration, national-level negotiation of DAA price, and National Reimbursement Drug List (NRDL) updates — all of which have laid a foundation for eliminating hepatitis C as a public health threat (5).

In 2021, National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, Ministry of Public Security, Ministry of Civil Affairs, Ministry of Justice, Ministry of Finance, National Healthcare Security Administration, and National Medical Product
The National Plan includes seven key prevention and control tasks and strategies: “five strengthenings, one expanding, and one implementation.” The first is strengthening publicity and education, popularizing HCV knowledge and improving public awareness of HCV control and prevention. The second is to strengthen comprehensive prevention interventions among key populations, nosocomial infection control, blood safety, and epidemiological investigations. The third is to expand HCV testing and improve detection rates by implementing the strategies of “testing all in need” in medical institutions and among key populations, “testing all of those with the willingness to be tested” for the general public, and “nucleic acid testing for anyone tested positive for anti-HCV.” The fourth is to strengthen referrals and standardized treatment by establishing a designated hospital healthcare service model for “treating all eligible” people living with chronic HCV infection with the aim to improve treatment coverage and cure rates. The fifth is to implement healthcare insurance policies and NRDL that reduce patients’ financial burden and improve the affordability of care. The sixth is to strengthen the supply and availability of HCV medicines, and promote a “DTP (Direct to Patient) pharmacy” mechanism with a sustainable drug supply that improves access to affordable treatment. The seventh is to strengthen information management and improve scientific monitoring and evaluation, including improving HCV case report quality, establishing and improving information management systems, strengthening data analyses and applications, and improving early warning mechanisms for cluster outbreaks.

For guaranteeing measures, the National Plan has “four intensifications and one mobilization.” The first is to intensify organization and leadership, including establishment of a national leadership group and an expert group, and clarification of the responsibilities of medical and health institutions. The second is to intensify capacity building, including laboratory and professional workforce capacity. The third is to mobilize social forces to participate in hepatitis C control and prevention. The fourth is to intensify scientific research and international cooperation. The fifth is to intensify supervision and National Plan fulfillment.

The National Plan is an important component of the Healthy China construction, which reflects a people-centered developmental philosophy and strengthens the “four-party responsibilities” of governments, departments, communities, and individuals. The National Plan was jointly issued by nine governmental departments, reflecting government leadership, departmental coordination, integration of treatment and prevention, and deepening of the “integration of medical treatment, medical insurance, and medicine supplies.” The National Plan references the WHO targets of the Global Health Sector Strategy on Viral Hepatitis and interim guidance for country validation of hepatitis elimination (7). The National Plan’s overall goal, phased targets, and phased strategies and measures are in accordance with China’s current situation and the Healthy China construction planning.
China faces several challenges to the elimination of hepatitis C as a public health threat by 2030. First, the number of patients with chronic hepatitis C in China is relatively large and the risk of HCV transmission still exists, leading to the potential of a huge burden of hepatitis C-related liver cirrhosis and HCC. Second, the “integration of medical treatment, medical insurance, and medicine supplies” is not enough, and mechanisms for integrating hospitals and centers for CDCs are not yet smooth. The “testing all in need” and “treating all eligible” strategies are not yet fully implemented, and the accessibility and affordability of medicine are inadequate. There are large gaps between targets and current progress, such as for testing and treatment coverage (8). Third, department attention, input, and effective measures are insufficient in some regions. The number and capacity of relevant health workers need to be increased and strengthened urgently.

It is critically important to fully promote and implement the national hepatitis C elimination action plan. First, more financial resources are needed to be invested and laboratory and professional workforce capacity are needed to be strengthened. Second, comprehensive strategies and measures should be implemented that can reduce both incidence and prevalence, including accelerating the HCV elimination working mechanism, establishing a designated medical service model, integrating resources, strengthening publicity and education, popularizing hepatitis C knowledge, strengthening comprehensive intervention, expanding testing, improving the detection rate of HCV, strengthening referral and standardized treatment, and increasing antiviral treatment coverage and cure rate of people living with HCV. Third, hepatitis C elimination should be integrated with Human Immunodeficiency Virus (HIV) control and prevention since they share the similar route of transmission. Comprehensive interventions should be strengthened among injecting drug users and other key populations vulnerable to HIV and sexually transmitted infections (STIs), including methadone maintenance treatment (MMT), needle exchange, and condom use promotion. Anti-HCV testing should be expanded among drug users receiving MMT, people seeking HIV voluntary counseling and testing service, people living with HIV and their spouse or sexual partners, and other key populations vulnerable to HIV and STIs. Fourth, it is vital to implement appropriate medical insurance policies that increase outpatient reimbursement, improving accessibility and affordability of diagnosis and treatment. Fifth, greater investment in research and development for hepatitis C elimination is needed.

### TABLE 1. Targets of the National Action Plan for Eliminating Hepatitis C as a Public Health Threat (2021–2030) by Year.

| Target | 2021 | 2025 | 2030 |
|--------|------|------|------|
| 1. Establishment of a working mechanism for hepatitis C elimination | √ | √ | √ |
| 2. Designation of at least one hospital per county qualified for HCV antiviral treatment | | | |
| 3. Percent of general hospitals of level-2 or above that can conduct anti-HCV testing | 100% | 100% | 100% |
| 4. Percent of general hospitals of level-2 or above that can conduct HCV RNA testing | 100% | 100% | 100% |
| 5. Percent of clinical blood tested for HCV RNA at the national level | 100% | 100% | 100% |
| 6. Percent of safe injections at medical institutions | 100% | 100% | 100% |
| 7. Percent of injection drug users (IDUs) covered by interventions | >80% | >80% | >80% |
| 8. Establishment of a national hepatitis C control and prevention information system | | | |
| 9. Percent increase of hepatitis C knowledge in the general public compared with a 2020 baseline | – | 10% | 20% |
| 10. Percent of newly reported anti-HCV positive cases tested for HCV RNA | – | >90% | >95% |
| 11. Percent of newly reported chronic hepatitis C patients who receive antiviral therapy | – | >80% | >80% |
| 12. Percent of all reported chronic hepatitis C patients who receive antiviral therapy | – | – | >80% |
| 13. Clinical cure rate of chronic hepatitis C patients who receive antiviral therapy | – | >95% | >95% |
| 14. Percent of healthcare professionals that received HCV-related training | – | >90% | 100% |
| 15. Percent of healthcare professionals who have received HCV-related training and are rated as qualified | – | >95% | >95% |

Note: “−”represents not applicable.
China’s hepatitis C elimination model must fit its actual situation.

*Corresponding author: Zhongfu Liu, liuzhongfu@chinaaids.cn.

1 National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Submitted: July 12, 2022; Accepted: July 21, 2022

REFERENCES

1. World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016–2021. Geneva: World Health Organization; 2021. https://apps.who.int/publications/i/item/progress-report-on-hiv-viral-hepatitis-and-sexually-transmitted-infections-2019.

2. Cui FQ, Zhuang H. Interpretation of Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: progress in eliminating viral hepatitis. Chin J Front Med Sci (Electron Vers) 2021;13(10):1–4. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2021&filename=YXQY202110002&uniplatform=NZKPT&v=DZVAFYxbA9M3w96R4WJpNR9-CaR6ua9EBINy9vTvTeN9L.

3. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. 2016. https://www.afro.who.int/publications/global-health-sector-strategy-viral-hepatitis-2016-2021, [2022-6-27].

4. National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, Ministry of Science and Technology, Ministry of Industry and Information Technology, Ministry of Public Security, et al. Action plan for the prevention and treatment of viral hepatitis in China (2017–2020). Chin J Viral Dis 2018;8(1):1 – 5. http://dx.doi.org/10.16505/j.2095-0136.2018.0001. (In Chinese).

5. Cui FQ, Zhuang H. Progress in prevention and control of viral hepatitis since the establishing of the People’s Republic of China. Chin J Hepatol 2021;29(8):725 – 31. http://dx.doi.org/10.3760/cma.j.cn501113-20210722-00351. (In Chinese).

6. National Health Commission of China. National plan for elimination action of hepatitis C as a public health threat (2021–2030). 2021. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec9e6d14d8291c53094
06603153.shtml?R0NMK6u0uOC=1654310439640. [2022-6-4]. (In Chinese).

7. World Health Organization. Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization. 2021. https://apps.who.int/iris/handle/10665/341652.

8. Ding GW, Pang L, Wang XC, Ye SD, Hei FX. Analysis of baseline characteristics and treatment status of hepatitis C in sentinel hospitals from 2017 to 2019. Chin J Hepatol 2020;28(10):844 – 9. http://dx.doi.org/10.3760/cma.j.cn501113-20200901-00492. (In Chinese).
Identifying the Optimal Age for Herpes Zoster Vaccination — Yichang City, Hubei Province, China, 2017–2019
Meiying You1,*, Tianqi Wang2,*, Miaomiao Wang1, Wei Jiang3, Jing Jiang3, Xudong Li1, Yuehua Hu1,*, Dapeng Yin4,*

Summary
What is already known about this topic? Herpes zoster (shingles) is a common skin condition in older adults, which usually presents as a painful rash with blisters. Vaccination is the most effective method to prevent shingles. However, there is not sufficient population-based epidemiological data in China to optimize the timing of zoster vaccination.

What is added by this report? Clustering analyses of population-wide epidemiological data from the Healthcare Big Data Platform in Yichang, China showed that the average annual zoster incidence is the highest among people 55 years or older, at 10 cases per thousand persons per year, making this age group the optimal target population for vaccination. Incidence was lower but increased with age among younger adults, 28–54 years old.

What are the implications for public health practice? With limited vaccination resources, zoster vaccinations should be targeted at adults 55 years or older who are at the greatest risk for shingles. Research should be conducted to understand the risk of shingles among young and middle-aged adults and identify triggers of shingles: potentially leading to preventive measures.

Herpes zoster (shingles) is a skin condition caused by the reactivation of varicella-zoster virus along dorsal nerve roots to the nerve root distribution on the skin, which causes a painful rash with blisters. Shingles mainly affect immunocompromised individuals and older adults (1). The most common complication of shingles is postherpetic neuralgia: a debilitating, burning pain that lasts long after the shingles blisters have healed. Treatment of shingles with antivirals can shorten the length and severity of shingles, but antiviral therapy should be started within 72 hours of the onset of the acute shingles rash and usually cannot be started in time (2). As such, vaccination is the best preventive measure. Recombinant zoster vaccines have been marketed in China for two years. Selecting the most suitable vaccine recipients can promote the implementation of the vaccine in China and effectively reduce the incidence of shingles. This study used a clustering methodology to partition age groups by shingles incidence using diagnostic data from January 1, 2017 through December 31, 2019 in Yichang, China. The highest risk age group was adults 55 years or older, with an average incidence of 10.13 episodes of shingles per 1,000 person-years. This age group is therefore the priority target for zoster vaccination. Among adults aged 28–54 years, shingles incidence increased with increasing age, requiring further study to identify potential shingles triggers.

In 2020, the recombinant zoster vaccine (RZV) was approved by China’s National Medical Products Administration for market authorization. RZV is a two-dose, subunit vaccine of a recombinant glycoprotein E with a novel adjuvant (AS01B) shown to prevent shingles in adults aged 50 and above with normal immune functioning (3). RZV is administered in 0.5-mL intramuscular injections in the deltoid region of the upper arm, with the 2 doses separated by 2–6 months. Post-licensure data showed vaccine efficacy to be 97.2% (95% CI: 93.7–99.0) in adults 50 years or older, with a relatively long duration of protection; 4 years after vaccination, efficacy is 93.1% (95% CI: 81.2–98.2) among adults greater than or equal to 50 years and 87.9% (95% CI: 73.3–95.4) among adults greater than or equal to 70 years. RZV is a non-program vaccine; the 2-dose series costs approximately CNY3,240.

Effective and efficient use of RZV requires the identification of an optimal target population for vaccination. Because target population identification has great public health significance, real-world evidence from a large population-base of epidemiological data is needed. Real-world data from Yichang, China provided an epidemiological basis for determining the optimal age for shingles vaccination. Under the constraint of limited vaccine resources, maximizing public health value requires maximizing the reduction of the burden of disease by careful selection of priority target populations.
Data for this study came from the government-led Healthcare Big Data Platform in Yichang from January 1, 2017 through December 31, 2019. All shingles outpatient and inpatient cases from 49 medical institutions in 6 urban districts of Yichang were included in this study’s analyses. Shingles case inclusion criteria were an International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) disease code containing "B02" and diagnosis of "shingles." Clinical diagnostic criteria for case definitions required the following three symptoms or signs to be present simultaneously: clusters of blisters in the affected skin and distribution along a unilateral peripheral nerve dermatome, neuralgia with local lymph node enlargement, and normal skin outside of the affected dermatome.

This study estimated the number of permanent urban residents in all ages in 2017–2019 based on the total population of Yichang in 2020. The study calculated the year-of-age-specific incidences of shingles for 0 through 79 years of age; 80 years and above was considered as 1 age group. Age-group-specific shingles incidences during the 2017–2019 study period were ordered for cluster analysis with the K-means method. The K-means method is an unsupervised learning technique in which objects (year-of-age groupings for this study) are divided into clusters based on the epidemiological distance between objects, so that the data (incidence) would be maximally similar within a cluster but maximally dissimilar between clusters (4). The initial step was to determine the number of clusters, k, using the silhouette coefficient (SC) method. Values of SCs were between −1 and 1. The closer the SC values were to 1, the more optimal was the clustering. Once the optimal number of clusters was determined, the K-means method was used for cluster analysis. Data were analyzed using SPSS software (version 27.0, IBM Corp, Armonk, NY, USA), and the model was implemented in Python (version 3.10.4, Python Software Foundation, Fredericksburg, VA, US).

Based on the number of permanent (more than 6 months) urban residents and their duration of residence during 2017 to 2019, this study’s analytic dataset contained 5,691,939 person-years of observation: 2,872,042 men person-years and 2,819,897 women person-years. The overall incidence of shingles was 5.82 per 1,000 person-years (33,130/5,691,939); the incidence among women was 6.29 per 1,000 person-years (17,743/2,819,897) and the incidence among men was 5.36 per 1,000 person-years (15,387/2,872,042). Shingles incidence was thus significantly greater in women (P<0.05).

Shingles occurred in all age groups and increased with age. The incidence of shingles among children 0–9 years of age was low, but not 0. Shingles incidence increased significantly between 10 and 27 years of age and then plateaued between 30 and 50 years of age; incidence increased again after 55 years of age (Figure 1).

![Figure 1. Age-specific incidence of shingles from 2017–2019 in Yichang, China. Notes: Age-specific incidence in 2017–2019 was calculated by the following formulas: n=total urban permanent resident population×age composition ratio of Yichang in 2020; total observed person-years=n×observation years:

\[
\text{age-specific incidence}=\frac{\text{number of shingles cases at all ages}}{\text{total observed person – years in the fixed time period}}.
\]
There were 3 age-group categories that differed by incidence (k=3) (Figure 2): 0–27 years, 28–54 years, and 55 years and above (Figure 3). Mean shingles incidences were 1.86 per 1,000 person-years for 0–27-year-olds, 4.85 per 1,000 person-years for 28–54-year-olds, and 10.13 per 1,000 person-years for those 55 years or older.

**DISCUSSION**

This study found that individuals of 55 years or older had the highest average incidence of shingles at 10.13 per 1,000 person-years of observation, accounting for 56.50% (18,720/33,130) of all cases in Yichang. Thus, shingles mainly affects older adults. China has more elderly people than any other country, and the proportion of the elderly population in China is becoming one of the highest in both Asia and the world (5). In generalizing these results from Yichang to China’s population using the 6th population census, China is expected to have 12.58 million patients with shingles, including 5.27 million among those 55 years or older — an enormous burden of disease.

This study of age-specific shingles incidence showed that vaccinating people 55 or older would have the greatest impact on the burden of shingles. However, the recommended age for shingles vaccination needs to also consider vaccine clinical trial populations and results, post-marketing monitoring, and other factors such as economic analyses. This study recommends conducting comprehensive socioeconomic evaluation and impact research with the Yichang Information System during vaccine implementation to provide a robust evidence base to refine vaccine target population selection.

This study found a plateau in incidence among 28–54-year-olds, although occurring with a relatively large incidence. In generalizing the 6th census data to all of China, it is estimated that 5.11 million young and middle-aged individuals will have shingles episodes — similar to the expected number of elderly cases (5.27 million). Shingles in this age are clearly worthy of attention. In addition to age, immunodeficiency is a well-known risk factor for shingles. The advancing age of onset (younger and younger ages) may be related to common, immuno-compromising, environmental conditions of modern middle-aged and young adults: such as high stress, low immunity, or fatigue. Case-control studies should be conducted in this age group to determine whether there is an association between these factors and shingles, and if so, to identify preventive measures.

Shingles incidence in Yichang from 2017 to 2019 was 5.82 per 1,000 person-years, which is slightly higher than in other studies (3–5 per 1,000 person-years) (6). Differences could be due to a variety of factors, such as genetic make-up, region, or study year. That the incidence of shingles increased with age and was concentrated in people 55 years or older is consistent with other studies (7). Similarly, the higher incidence in women is consistent with studies in Guangdong, China and the Republic of Korea (8–9). However, the mechanistic relationship between sex and shingles remains unclear (10).

Previous shingles epidemiological data in China was among people more than 50 years of age. Data in this study came from the Healthcare Big Data Platform of Yichang, which includes permanent urban residents of
all ages. This study’s inclusive and large sample size allows for more fine-grained analyses. It was resultantly able to not only observe the entire population, but also refine analyses to obtain age-specific incidence rates all the way down to 1-year-olds. The objective and scientific clustering method used created age groupings based on clusters of single-year incidence rates. The finding that individuals 55 years or older had the highest shingles incidence, combined with census data on age structure, allowed a conclusion that, given limited immunization resources, the greatest public health benefit can be achieved by vaccinating that age group.

The study was subject to at least two limitations. First, no shingles monitoring system exists in the mainland of China. Hence some cases might not have been detected based on the big data from the hospital information system, underestimating the incidence. Second, demographic data for 1-year-olds in Yichang from 2017 to 2019 were not available. As such, data from the 7th population census in 2020 were used to estimate incidences in age groups from 2017 to 2019.

In conclusion, based on the epidemiological data analysis of the urban population in Yichang, China, individuals 55 years or older had the highest risk group of shingles. This age group should be considered as the priority target population for shingles vaccination. Attention should also be paid to the relatively high incidence of shingles in young and middle-aged people.

**Conflicts of interest:** No conflicts of interest.

**Funding:** 2020 Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund Key research topic; the research of varicella disease burden and economic evaluation of vaccination (L202008).

doi: 10.46234/ccdcw2022.137

---

**REFERENCES**

1. Herpes zoster Expert Consensus Working Group of Chinese Dermatologist Association. Herpes zoster expert consensus in China. Chin J Dermatol 2018;51(6):403–8. http://dx.doi.org/10.3760/cma.j.issn.0412-4030.2018.06.001. (In Chinese).
2. Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2017;96(10):656–63. https://pubmed.ncbi.nlm.nih.gov/29431387/.
3. National Medical Products Administration. The recombinant herpes zoster vaccine was approved. 2019. https://www.nmpa.gov.cn/zhuanti/ypsqgg/gggzjzh/201905221507001437.html. [2020-8-10]; (In Chinese).
4. Sun L, Liu MH, Xu JC. K-means clustering algorithm using optimal initial clustering center and contour coefficient. Fuzzy Syst Mathem 2022;36(1):47–65. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=mhxtysx202201005. (In Chinese).
5. Du P, Li L. Long-term trends projection of China’s population aging in the new era. J Renmin Univ China 2021;35(1):96–109. http://xuebao.ruc.edu.cn/wk33/CN/Y2021/V35/I1/96. (In Chinese).
6. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4(6):e004833. http://dx.doi.org/10.1136/bmjopen-2014-004833.
7. Yin DP, Van Oorschot D, Jiang N, Marijum A, Saha D, Wu ZH, et al. A systematic literature review to assess the burden of herpes zoster disease in China. Expert Rev Anti Infect Ther 2021;19(2):165–79. http://dx.doi.org/10.1080/14787210.2020.1792290.
8. Zhu Q, Zheng HZ, Qu HY, Deng HH, Zhang JK, Ma WJ, et al. Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China. Hum Vaccin Immunother 2015;11(8):2113–8. http://dx.doi.org/10.1080/21645515.2015.1016672.
9. Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci 2014;29(12):1706–10. http://dx.doi.org/10.3346/jkms.2014.29.12.1706.
10. Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006;16(9):692–5. http://dx.doi.org/10.1016/j.annepidem.2005.12.002.
Characteristics and Associated Factors of E-cigarette Use Among Secondary School Students — 6 PLADs in China, 2021

Zhaobin Qi; Bingliang Lin; Xiaoyun Xie; Lin Xiao

Summary

What is already known about this topic?
Previous studies on electronic cigarette (e-cigarette) use in China among secondary school students have provided information on the awareness and usage of e-cigarettes.

What is added by this report?
This study not only described e-cigarette usage rates, but also explored the characteristics of e-cigarette users’ behavior and factors associated with the current use of e-cigarettes among secondary school students.

What are the implications for public health practice?
E-cigarette use among secondary school students, especially among vocational senior high school students, requires more attention. Although some policies have been developed to protect youths from the harmful effects of e-cigarettes, enforcement of these policies needs to be strengthened.

The 2021 World Health Organization Report on the Global Tobacco Epidemic highlighted the addictive nature of e-cigarettes and called for regulation. China has implemented policies to protect youth from e-cigarettes, such as the revised Law of the People’s Republic of China on the Protection of Minors banning the sale of electronic cigarettes to minors. This study was conducted based on the China National Youth Tobacco Survey (NYTS) framework with secondary school students [including junior high school (JHS) students, general senior high school (GSHS) students, and vocational senior high school (VSHS) students] in 2021, which was approved by the Institutional Review Board of China CDC (No. 202110). A total of 52,879 secondary school students from 6 provincial-level administrative divisions (PLADs) in China were asked about e-cigarette usage, purchase behaviors, and factors associated with the current e-cigarette usage to evaluate the previous policies and provide reference for next steps.

Using the results of the 2019 China NYTS, one PLAD with a relatively high e-cigarette use rate and one PLAD with a relatively low e-cigarette use rate were selected in each of the central, eastern, and western regions of China. Consequently, Beijing Municipality; Guangdong, Hunan, Hubei, and Sichuan provinces; and Ningxia Hui Autonomous Region were selected. A 3-stage stratified cluster random sampling was employed in each PLAD. First, 5 districts (urban areas) and 5 counties (rural areas) were selected in each PLAD using a proportionate to population size sampling scheme (PPS). Second, 3 JHSs, 2 GSHSs, and 1 VSHS were selected using the PPS method within each selected district and county. Third, within selected schools, 1 class was randomly selected in each grade and all the students in the selected class were interviewed (if the class size was less than 30, the sample class was supplemented). Overall, 180 JHSs, 121 GSHSs, and 52 VSHSs from 60 districts/counties of the 6 PLADs participated in the survey from September to December 2021. A total of 52,879 eligible students (26,751 JHS students, 18,851 GSHS students, and 7,277 VSHS students) completed the questionnaire, of which 27,548 were male and 25,331 were female. The overall survey response rate was 95.2%.

In the interviews, structured paper-based questionnaires with no logical skips were used. Ever e-cigarette users (EES) were defined as students who had used e-cigarettes in the past; simply trying an e-cigarette one time qualified a student for this designation. Current e-cigarette users (CES) were students who had used e-cigarettes at least once in the past 30 days, and current smokers (CS) were students who had used cigarettes at least once in the past 30 days. All participants were asked if they had noticed advertisements for e-cigarettes or related products in the past 30 days and if they believed e-cigarette use is addictive. In addition, students were asked about their pocket money for a week and their parents’ or close friends’ smoking status. In terms of behaviors around e-cigarette use, all the CES were asked about e-cigarette flavors and the way of their purchase. Prevalence rates
The proportion of students who saw advertisements in e-cigarette retail stores, shops/supermarkets/grocery stores, on websites, social media, TV/broadcasts, billboards, and in newspapers/journals was 15.2%, 12.6%, 7.3%, 5.9%, 5.0%, 3.2%, and 1.8%, respectively.

Potential factors associated with current e-cigarette use among secondary school students were explored using a two-level mixed effect model. The model indicated that students were more likely to use e-cigarettes if they were current cigarette smokers [odds ratio (OR)=9.745, 95% confidence interval (CI): 8.183–11.605], noticed e-cigarette advertisements in the past 30 days (OR=3.518, 95% CI: 3.012–4.108), had weekly pocket money >40 CNY (OR=1.415, 95% CI: 1.143–1.751), and had at least one parent smoking (OR=1.280, 95% CI: 1.089–1.505). Compared to those who had no close friends that smoked, students where all close friends smoked (OR=18.178, 95% CI: 11.953–27.645), most close friends smoked (OR=14.476, 95% CI: 10.950–19.137), or some close friends smoked (OR=5.415, 95% CI: 4.385–6.686) were more likely to use e-cigarettes. In addition, secondary school students who believed e-cigarettes could be addictive were less likely to use e-cigarettes (OR=0.606, 95% CI: 0.496–0.740). Students in the highest quantile districts/counties of e-cigarette sales to minors were more likely to have used e-cigarettes than in the lowest quantile districts/counties (OR=1.871, 95% CI: 1.101–3.177) (Table 2).

**DISCUSSION**

According to this study, 14.9% of secondary school students had used e-cigarettes and the current use rate was 3.0%. Males had a higher EES and CES prevalence rate than females. The prevalence rates of EES and CES among VSHS students were 26.0% and 7.0%, respectively. These were much higher than the rates observed among GSHS (15.4% and 2.6%) and JHS (11.4% and 2.2%) students. It was worth noting that the EES and CES prevalence rates among VSHS observed in 2019 NYTS were 20.5% and 4.5% respectively (2). Although the data from selected counties/districts in this study cannot be compared with the 2019 national-level data, the concern that e-cigarette use may be increasing among VSHS can be further studied.

Although there were some policies protecting youth from e-cigarette use that were enacted in 2018 and 2019, such as banning e-cigarette sales to minors,
TABLE 1. Ever and current e-cigarette use among secondary school students in six PLADs (2021).

| Characteristics     | Total      | Ever e-cigarettes use | Current e-cigarettes use | \( \chi^2 \) | \( P \) | \( \chi^2 \) | \( P \) |
|---------------------|------------|------------------------|--------------------------|------------|-------|------------|-------|
|                     | N (\%)    | n (\%)                |                          |            |       |            |       |
| Overall             | 52,879 (100.0) | 7,856 (14.9)            | 1,599 (3.0)              |            |       |            |       |
| Gender              |            |                        |                          |            |       |            |       |
| Male                | 27,548 (52.1)    | 5,626 (20.4)             | 1,196 (4.3)              | 1,409.07   | <0.001 | 340.20    | <0.001 |
| Female              | 25,331 (47.9)    | 2,230 (8.8)              | 403 (1.6)                |            |       |            |       |
| Area type           |            |                        |                          |            |       |            |       |
| Urban               | 21,375 (40.4)    | 2,640 (12.0)             | 722 (3.4)                | 133.84     | <0.001 |            |       |
| Rural               | 21,375 (40.4)    | 2,230 (8.8)              | 403 (1.6)                |            |       |            |       |
| School type         |            |                        |                          |            |       |            |       |
| JHS                 | 26,751 (50.6)    | 3,060 (11.4)             | 287 (1.9)                | 7,325.78   | <0.001 | 9,574.44  | <0.001 |
| GSHS                | 18,851 (35.6)    | 2,908 (15.4)             | 495 (2.6)                |            |       |            |       |
| VSHS                | 7,277 (13.8)     | 1,888 (26.0)             | 510 (7.0)                |            |       |            |       |
| PLAD                |            |                        |                          | 369.99     | <0.001 | 76.94     | <0.001 |
| Beijing             | 7,956 (15.0)     | 1,009 (12.7)             | 250 (3.1)                |            |       |            |       |
| Guangdong           | 8,536 (16.2)     | 1,015 (11.9)             | 213 (2.5)                |            |       |            |       |
| Hunan               | 8,576 (16.3)     | 1,769 (20.7)             | 370 (4.3)                |            |       |            |       |
| Hubei               | 9,531 (18.0)     | 1,250 (13.1)             | 233 (2.4)                |            |       |            |       |
| Ningxia             | 8,693 (16.4)     | 1,463 (16.8)             | 286 (3.3)                |            |       |            |       |
| Sichuan             | 9,587 (18.1)     | 1,350 (14.1)             | 247 (2.6)                |            |       |            |       |
| Weekly pocket money  |            |                        |                          | 482.74     | <0.001 | 215.51    | <0.001 |
| ≤10 CNY             | 15,433 (29.3)    | 1,743 (11.3)             | 287 (1.9)                |            |       |            |       |
| 11–40 CNY           | 17,846 (34.8)    | 2,353 (13.2)             | 416 (2.7)                |            |       |            |       |
| >40 CNY             | 19,443 (36.9)    | 3,730 (19.2)             | 893 (4.6)                |            |       |            |       |
| Current smoking     |            |                        |                          | 7,325.78   | <0.001 | 9,574.44  | <0.001 |
| Yes                 | 2,156 (4.1)      | 1,684 (78.2)             | 813 (37.8)               |            |       |            |       |
| No                  | 52,517 (95.9)    | 5,944 (11.8)             | 724 (1.4)                |            |       |            |       |
| Parents smoking     |            |                        |                          | 405.69     | <0.001 | 193.11    | <0.001 |
| None                | 23,941 (46.2)    | 2,709 (11.3)             | 444 (1.9)                |            |       |            |       |
| At least one        | 27,949 (53.8)    | 4,903 (17.6)             | 1,096 (4.0)              |            |       |            |       |
| Close friends smoking |          |                        |                          | 8,170.63   | <0.001 | 5,922.85  | <0.001 |
| None                | 36,908 (60.9)    | 2,574 (7.0)              | 223 (0.6)                |            |       |            |       |
| Some                | 14,166 (26.8)    | 4,030 (28.5)             | 822 (5.8)                |            |       |            |       |
| Most                | 1,425 (2.7)      | 987 (69.3)               | 425 (29.9)               |            |       |            |       |
| All                 | 356 (0.6)        | 260 (73.0)               | 128 (36.0)               |            |       |            |       |
| Noticed e-cigarette advertisement |        |                        |                          | 957.48     | <0.001 | 1,077.32  | <0.001 |
| Yes                 | 14,631 (28.0)    | 3,289 (22.5)             | 1,014 (6.9)              |            |       |            |       |
| No                  | 37,623 (72.0)    | 4,434 (11.8)             | 554 (1.5)                |            |       |            |       |
| E-cigarette addictive cognition |        |                        |                          | 2,656.18   | <0.001 | 902.48    | <0.001 |
| Yes                 | 14,774 (27.9)    | 1,473 (10.0)             | 281 (1.9)                |            |       |            |       |
| No                  | 38,105 (72.1)    | 6,376 (16.7)             | 1,311 (3.4)              |            |       |            |       |

Abbreviations: JHS=junior high school; GSHS=general senior high school; VSHS=vocational senior high school; PLAD=provincial-level administrative division; CNY=China Yuan.
TABLE 2. Factors associated with current e-cigarette use using a two-level mixed effect model.

| Parameter                          | β   | SE   | t-value | P       | OR (95% CI)         |
|------------------------------------|-----|------|---------|---------|---------------------|
| **Fixed part**                     |-----|------|---------|---------|---------------------|
| Intercept                          | -7.286 | 0.303 | -24.04  | <0.001  |                     |
| Gender                             |      |      |         |         |                     |
| Male                               | 0.494 | 0.091 | 5.43    | <0.001  | 1.639 (1.371–1.959) |
| Female                             |      |      |         |         | Ref                 |
| Area type                          |      |      |         |         |                     |
| Urban                              | -0.155 | 0.115 | -1.35   | 0.178   | 0.857 (0.683–1.073) |
| Rural                              |      |      |         |         | Ref                 |
| School type                        |      |      |         |         |                     |
| JHS                                |      |      |         |         | Ref                 |
| GSHS                               | 0.676 | 0.117 | 5.78    | <0.001  | 1.669 (1.562–2.472) |
| VSHS                               | 0.512 | 0.138 | 3.71    | <0.001  | 1.965 (1.568–2.482) |
| PLAD                               |      |      |         |         |                     |
| Guangdong                          |      |      |         |         | Ref                 |
| Beijing                            | 0.568 | 0.201 | 2.83    | 0.005   | 1.765 (1.189–2.619) |
| Hunan                              | 0.585 | 0.177 | 3.30    | 0.001   | 1.796 (1.267–2.545) |
| Hubei                              | 0.296 | 0.192 | 1.54    | 0.123   | 1.345 (0.922–1.962) |
| Ningxia                            | 0.217 | 0.198 | 1.10    | 0.274   | 1.242 (0.842–1.832) |
| Sichuan                            | 0.047 | 0.193 | 0.24    | 0.809   | 1.048 (0.716–1.533) |
| Weekly pocket money                |      |      |         |         |                     |
| ≤10 CNY                            |      |      |         |         | Ref                 |
| 11–40 CNY                          | 0.122 | 0.113 | 1.08    | 0.002   | 1.129 (0.905–1.408) |
| >40 CNY                            | 0.347 | 0.109 | 3.19    | 0.001   | 1.415 (1.143–1.751) |
| Current smoking                    |      |      |         |         |                     |
| Yes                                | 2.277 | 0.089 | 25.55   | <0.001  | 9.745 (8.183–11.605) |
| No                                 |      |      |         |         | Ref                 |
| Parents smoking                    |      |      |         |         |                     |
| None                               | 0.247 | 0.083 | 2.99    | 0.003   | 1.280 (1.089–1.505) |
| At least one                       |      |      |         |         | Ref                 |
| Close friends smoking              |      |      |         |         |                     |
| None                               |      |      |         |         | Ref                 |
| Some                               | 1.689 | 0.108 | 15.70   | <0.001  | 5.415 (4.385–6.686) |
| Most                               | 2.673 | 0.142 | 18.76   | <0.001  | 14.476 (10.950–19.137) |
| All                                | 2.900 | 0.214 | 13.56   | <0.001  | 18.178 (11.953–27.645) |
| Noticed e-cigarette advertisement  |      |      |         |         |                     |
| Yes                                | 1.258 | 0.079 | 15.89   | <0.001  | 3.518 (3.012–4.108) |
| No                                 |      |      |         |         | Ref                 |
| E-cigarette addictive cognition    |      |      |         |         |                     |
| Yes                                | -0.501 | 0.102 | -4.92   | <0.001  | 0.606 (0.496–0.740) |
| No                                 |      |      |         |         | Ref                 |
| E-cigarette sales to minors        |      |      |         |         |                     |
| More                               | 0.626 | 0.270 | 2.32    | 0.021   | 1.871 (1.101–3.177) |
| General                            | 0.479 | 0.215 | 2.23    | 0.027   | 1.615 (1.058–2.465) |
| Less                               |      |      |         |         | Ref                 |
| Random part                        |      |      |         |         |                     |
| 2 horizontal variances             | 0.288 | 0.058 | 4.97    | <0.001  |                     |

Abbreviations: SE=standard error; OR=odds ratio; CI=confidence interval; JHS=junior high school; GSHS=general senior high school; VSHS=vocational senior high school; PLAD=provincial-level administrative division; CNY=China Yuan.
prohibiting selling e-cigarettes on the internet, and banning advertisements of e-cigarettes on the internet (3–4). 67.0% of current e-cigarette users reported they were not rejected when they bought e-cigarettes in the past 30 days. In fact, 36.3% of current e-cigarette users bought e-cigarettes through the internet. This suggests that relevant e-cigarette policies were not well enforced.

Like other studies (5–6), the vast majority (58.3%) of e-cigarette users among secondary school students in this study used fruit-flavored e-cigarettes. Previous studies showed that flavors might attract youths to try e-cigarettes (7). On May 1, 2022, the Management Regulation of Electronic Cigarettes prohibited flavors except for tobacco flavor. The effect of this policy in reducing the attraction of e-cigarettes among adolescents should be examined in future studies.

Among CES, 52.9% smoked combustible cigarettes, which is much lower than the reported rate in adult populations (90.6%) (8). Additionally, our study found that the probability of currently smoking students who use e-cigarettes was 9.745 times that of non-smoking students, which indicates current smokers are more likely to use e-cigarettes. Our study also found that a smoking parent or friend increases the risk for secondary school students to use e-cigarettes. This is consistent with findings from previous studies (9–10).

In our study, a two-level mixed effect model revealed that “noticed e-cigarette advertisement” was associated with e-cigarette use (OR=3.518). Overall, 28.0% of secondary school students reported they had seen advertisements for e-cigarettes or related products in the past 30 days. This finding highlights the importance of prohibiting e-cigarette advertisements, especially near schools. Our study also found students who believed e-cigarettes could be addictive were less likely to use e-cigarettes (OR=0.606). This suggests that introducing e-cigarette information into health education could reduce e-cigarette use.

A potential limitation of this study is that the survey data was collected using a self-reported questionnaire, which may have led to an underreporting and recall bias. In addition, this study only uses quantitative research methods. Therefore, there is a lack of in-depth research and discussion on the reasons why secondary school students use e-cigarettes and their attitudes on using e-cigarettes.

In conclusion, e-cigarette use among secondary school students, especially among vocational senior high school students, requires more attention. Although there have been some policies enacted to protect youth from e-cigarettes, enforcement of these policies needs to be strengthened. Factors associated with e-cigarette use should be considered to guide new policies, such as health education and banning e-cigarette advertisements.

Conflicts of interest: No conflicts of interest.

Acknowledgements: All the colleagues from local institutions in the data collection. Yin Xi from WHO WPRO Office.

doi: 10.46234/ccdcw2022.126

* Corresponding author: Lin Xiao, xiaolin@chinacdc.cn.

1 Tobacco Control Office, Chinese Center for Disease Control and Prevention, Beijing, China.

Submitted: June 14, 2022; Accepted: June 28, 2022

REFERENCES

1. World Health Organization. WHO report on the global tobacco epidemic 2021: addressing new and emerging products. License: BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240032095. [2021-7-1].

2. Gao GF, Li XH. 2019 YGTS county report China. Beijing: People’s Medical Publishing House, 2022. (In Chinese).

3. State Administration of Market Supervision, State Tobacco Monopoly Administration. Notice on prohibiting the sale of electronic cigarette to minors. (2018-8-28)[2022-6-11]. http://www.gov.cn/gongbao/content/2020/content_5488930.htm. (In Chinese).

4. State Administration of Market Supervision, State Tobacco Monopoly Administration. Notice on further protection of minors from E-cigarettes. (2019-10-30)[2022-6-11]. http://www.gov.cn/xinwen/2019-11/01/content_5447612.htm. (In Chinese).

5. Leventhal AM, Miech R, Barrington-Trimis J, Johnston LD, O’Malley PM, Patrick ME. Flavors of e-cigarettes used by youths in the United States. JAMA 2019;322(21):2132 – 4. http://dx.doi.org/10.1001/jama.2019.17968.

6. Cullen KA, Gentzke AS, Sawdey MD, Chang JT, Anic GM, Wang TW, et al. E-cigarette use among youth in the United States, 2019. JAMA 2019;322(21):2095 – 103. http://dx.doi.org/10.1001/jama.2019.18387.

7. Bold KW, Kong G, Carullo DA, Camenga DR, Krishnan-Sarin S. Reasons for trying E-cigarettes and risk of continued use. Pediatrics 2016;138(3):e20160895. http://dx.doi.org/10.1542/peds.2016-0895.

8. Xiao L, Yin X, Di XB, Nan Y, Lyu TC, Wa YQ, et al. Awareness and prevalence of e-cigarette use among Chinese adults: policy implications. Tob Control 2022;31(4):498 – 504. http://dx.doi.org/10.1136/tobaccocontrol-2020-056114.

9. Hanewinkel R, Isensee B. Risk factors for e-cigarette, conventional cigarette, and dual use in German adolescents: a cohort study. Prev Med 2015;74:39 – 42. http://dx.doi.org/10.1016/j.ypmed.2015.03.006.

10. Ling MJY, Ahmad N, Yusoff MFM, Lim KH. Current e-cigarette use among in-school adolescents in West Malaysia: examining the interactions between sociodemographic characteristics and lifestyle risk behaviours. PLoS One 2022;17(1):e0263555. http://dx.doi.org/10.1371/journal.pone.0263555.
Preplanned Studies

Prevalence of Metabolic Syndrome and Risk Factors Among Chinese Adults: Results from a Population-Based Study — Beijing, China, 2017–2018

Jufen Liu1,2,∗; Qingping Liu1,3; Zhiwen Li1,2; Jing Du1; Chao Wang1; Yanlin Gao3; Zaihua Wei1; Jing Wang3; Yunping Shi3; Jianing Su3; Yang Liu1; Ping Wang3; Chunyan Xie3; Gang Li3; Bing Shao4,∗; Le Zhang1,2,∗

Summary

What is already known about this topic?
Metabolic syndrome (MetS) is one of the most easily available health indicative markers for cardiovascular diseases, and it has become a major public health problem worldwide due to increasing urbanization and aging populations. The prevalence of MetS increased dramatically in China, however, there are no records of MetS defined by the 2017 Chinese Diabetes Society for Beijing by far.

What is added by this report?
In this study, the data of 24,412 participants aged 18–74 years from a large population-based study in Beijing was collected. The overall prevalence of MetS among Beijing residents was 24.5%. The prevalence was 35.2% in males and 15.4% in females.

What are the implications for public health practice?
Effective public health strategies should target males, people with older age, lower education, higher body mass index, smokers, those who drink alcohol, those who are unemployed or retired, and those who live in rural areas on MetS prevention and control.

Metabolic syndrome (MetS) is characterized as insulin resistance, obesity, hypertension, glucose intolerance, and dyslipidemia. MetS is associated with elevated cardiovascular diseases and chronic diseases. With increasing urbanization and aging populations, the prevalence of MetS increased dramatically in China and became a major public health challenge (1). Meta-analysis revealed that pooled prevalence in the mainland of China was 24.5% during 2005–2015 (2). Genetics, environmental influence, physical activity, diet, and behavior all influence the prevalence of both MetS and its components (3). Beijing, a metropolitan city with an aging population, had no record of the prevalence of MetS defined by the new criteria for Chinese adults. The current study estimated the prevalence of MetS and its risk factors in Beijing based on a recent large sample study conducted in 2017–2018. The total prevalence of MetS was estimated to be 24.5% among Beijing residents. Males, especially those who lived in the outer suburbs, smokers, and those of older age were associated with an increased risk for MetS.

The data used in the current study came from the baseline dataset of Beijing Population Health Cohort study, which was designed to measure air pollution and health outcomes. Details of the study have been described in a previous publication (4). A stratified, random cluster sampling method was used to select participants from a general population in Beijing in 2017–2018. To ensure the sample size, the survey was conducted with an estimated sample, and if the respondent was not available, another candidate in the list would be surveyed then. Our study included 24,990 individuals from 16 districts, which included urban areas, suburban areas, and outer suburbs to represent a general population of Beijing. Participants were permanent residents living in Beijing for more than 2 years and aged 18–74 years. Among them, 578 individuals without identification number (ID) or repetitive ID were excluded; 24,412 individuals were included in the study. MetS was diagnosed according to the China Diabetes Society (CDS) criteria, which was newly released in 2017 according to Chinese guidelines, where a person has MetS if he or she meets 3 or more of the following criteria: 1) a waist circumference of ≥90 cm for men and ≥85 cm for women; 2) a fasting plasma glucose (FPG) of ≥6.1 mmol/L or previously diagnosed diabetes; 3) a systolic blood pressure (SBP) of ≥130 mmHg, a diastolic blood pressure (DBP) of ≥85 mmHg, or previously diagnosed hypertension; 4) a fasting triglyceride level
of ≥1.7 mmol/L; and 5) a high-density lipoprotein cholesterol (HDL-C) of <1.04 mmol/L (5).

The prevalence was calculated according to demographic and lifestyle factors and compared means using t-tests and distributions of categories using chi-squared tests. Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for the main potential confounding variables, including age, body mass index (BMI), education, occupation, smoking habits, alcohol use, and other factors. All data were analysed using SPSS Statistics for Windows (version 20.0, IBM Corp., Armonk, NY, US). Two-tailed P values <0.05 were considered statistically significant.

Of the total 24,412 participants in the study, 11,418 males and 12,994 females were surveyed. The total prevalence of MetS was 24.5% among Beijing residents. The prevalence of MetS was 35.2% in male participants and 15.4% in female participants. Subjects with MetS were more likely to be 55 years old and above, male, unemployed/student/retired, less educated, smoker, and drinker. (Table 1)

| Characteristics                  | MetS          | Control        | P     | Prevalence of MetS |
|----------------------------------|---------------|----------------|-------|--------------------|
| Age, years Mean (SD)             | 52.1 (12.9)   | 43.8 (14.4)    | <0.001|                   |
| BMI, kg/m² Mean (SD)             | 27.8 (3.7)    | 24.2 (3.8)     | <0.001|                   |
| Han ethnic                       | 4,828 96.2    | 1,486 95.8     | 0.199 | 24.5               |
| Sex                              | <0.001        |                |       |                    |
| Male                             | 3,301 65.8    | 6,065 39.1     |       | 35.2               |
| Female                           | 1,719 34.2    | 9,454 60.9     |       | 15.4               |
| Age group (years)                | <0.001        |                |       |                    |
| ≤24                              | 65 1.3        | 1,123 7.2      |       | 5.5                |
| 25–34                            | 636 12.7      | 4,233 27.3     |       | 13.1               |
| 35–44                            | 662 13.2      | 2,771 17.9     |       | 19.3               |
| 45–54                            | 1,055 21.0    | 2,981 19.2     |       | 26.1               |
| 55–64                            | 1,764 35.1    | 3,048 19.6     |       | 36.6               |
| ≥65                              | 838 16.7      | 1,363 8.8      |       | 38.1               |
| BMI group                        | <0.001        |                |       |                    |
| Normal                           | 1,057 21.1    | 9,732 62.7     |       | 9.8                |
| Overweight                       | 2,806 55.9    | 4,857 31.3     |       | 36.6               |
| Obese                            | 1,157 23.0    | 930 6.0        |       | 55.4               |
| Education                        | <0.001        |                |       |                    |
| Primary school or lower          | 617 12.3      | 1,143 7.4      |       | 35.0               |
| Junior high school               | 1,442 28.7    | 2,878 18.5     |       | 33.4               |
| Senior high school               | 1,142 22.7    | 2,949 19.0     |       | 27.9               |
| College                          | 808 16.1      | 3,174 20.5     |       | 20.3               |
| Undergraduate and above          | 1,011 20.1    | 5,375 34.6     |       | 15.8               |
| Marital status                   | <0.001        |                |       |                    |
| Married                          | 4,601 91.7    | 12,787 82.4    |       | 26.5               |
| Divorced/separated               | 102 2.0       | 300 1.9        |       | 25.4               |
| Widowed                          | 119 2.4       | 242 1.6        |       | 33.0               |
| Single                           | 198 3.9       | 2,190 14.1     |       | 8.3                |
| Occupation                       | <0.001        |                |       |                    |
| Farmer, worker, and business     | 1,072 21.4    | 2,985 19.2     |       | 26.4               |
| Leader, clerk, and technical     | 1,994 39.7    | 8,123 52.3     |       | 19.7               |
| Others                           | 456 9.1       | 1,459 9.4      |       | 23.8               |
| Unemployment, student, retirement| 1,498 29.8    | 2,952 19.0     |       | 33.7               |
There was a significant difference between male and female subjects. The mean values for BMI, waist circumference, FPG, and serum triglycerides were higher in males than those in females, while HDL-C was higher in females than in males ($P<0.001$ for all comparisons). (Table 2)

Multiple logistic regression showed that males, especially those with older age, lower education, higher BMI, smoking, alcohol use, and living in rural areas were associated with MetS. (Table 3)

**DISCUSSION**

Based on the baseline dataset of this large population-based study, a quarter of participants had MetS. With the disease burden increasing, especially for chronic diseases, understanding the epidemiology of MetS and exploring risk factors of MetS would be an effective approach for disease prevention and health promotion. This study added evidence that nearly one-fourth of the Beijing residents in our study had MetS and implied that special attention should be paid among males, people with older age, lower education, higher BMI, smoker, and those lived in rural areas, for the prevention of MetS.

Few country-wide studies were conducted to describe the epidemiology of MetS in adults for all age groups; a previous study focused on older adults ($\geq 60$ years) or middle-aged people (35–59 years) as they were more susceptible to chronic cardiovascular disease (6). Using the updated CDS criterion (2017), the current study revealed the prevalence in a general population aged 18–74 years. The prevalence of MetS among Beijing residents (24.5%, 95% CI: 24.0%–25.5%) was generally consistent with a 2017 study of MetS in Beijing residents aged from 18 to 79 years (25.6%) (7). The prevalence of MetS in this study was higher than general Xinjiang residents (20.9%) (8) and Qingdao residents (17.8%) (9). Current study showed that the prevalence of MetS

**TABLE 2. Characteristics of components of MetS among adults in Beijing, China, 2017–2018.**

| Characteristics       | Male (N=11,418) | Female (N=12,994) | P     |
|-----------------------|-----------------|-------------------|-------|
|                       | Mean            | SD                | Mean  | SD                |       |
| Waist circumference (cm)| 90.05           | 10.898            | 81.17 | 10.872            | <0.001|
| SBP (mmHg)            | 130.16          | 17.937            | 123.06| 19.582            | <0.001|
| DBP (mmHg)            | 83.11           | 11.062            | 77.90 | 12.550            | <0.001|
| FPG (mmol/L)          | 5.85            | 1.769             | 5.53  | 1.515             | <0.001|
| Triglycerides (mmol/L)| 2.02            | 2.079             | 1.44  | 1.126             | <0.001|
| HDL-C (mmol/L)        | 1.31            | 0.325             | 1.49  | 0.335             | <0.001|

Note: Data were presented as mean and standard deviation for continuous variables or percentage for categorical variables. P value in t-test for means or $\chi^2$ test for proportion differences between males and females. Abbreviations: DBP=diastolic blood pressure; FPG=fasting plasma glucose; HDL-C=high-density lipoprotein cholesterol; SBP=systolic blood pressure; MetS=metabolic syndrome; SD=standard deviation.
TABLE 3. Factors associated with MetS by sex in Beijing, China, 2017–2018.

| Characteristics                          | Adjusted odds ratio and 95% CIs | Male                  | Female               |
|------------------------------------------|---------------------------------|-----------------------|----------------------|
| Age group (years)                        |                                 |                       |                      |
| ≤24                                      | 1.000                           | 1.000                 |                      |
| 25–34                                    | 2.453 (1.737–3.463)             | 1.469 (0.692–3.119)   |                      |
| 35–44                                    | 3.754 (2.600–5.418)             | 2.854 (1.310–6.219)   |                      |
| 45–54                                    | 5.445 (3.773–7.857)             | 4.229 (1.952–9.162)   |                      |
| 55–64                                    | 6.154 (4.238–8.934)             | 11.438 (5.248–24.933) |                      |
| ≥65                                      | 6.120 (4.127–9.077)             | 14.502 (6.588–31.921) |                      |
| BMI group                                |                                 |                       |                      |
| Normal                                   | 1.000                           | 1.000                 |                      |
| Overweight                                | 3.554 (3.200–3.946)             | 4.564 (3.979–5.237)   |                      |
| Obese                                    | 8.547 (7.357–9.930)             | 12.545 (10.441–15.073)|                      |
| Education                                |                                 |                       |                      |
| Primary school or lower                  | 0.967 (0.764–1.224)             | 1.187 (0.887–1.588)   |                      |
| Junior high school                       | 1.154 (0.975–1.366)             | 1.377 (1.065–1.781)   |                      |
| Senior high school                       | 1.290 (1.104–1.506)             | 1.202 (0.936–1.543)   |                      |
| College                                  | 1.318 (1.142–1.520)             | 1.338 (1.066–1.680)   |                      |
| Undergraduate and above                  | 1.000                           | 1.000                 |                      |
| Marital status                           |                                 |                       |                      |
| Married                                  | 1.000                           | 1.000                 |                      |
| Divorced/separated                       | 1.209 (0.868–1.686)             | 0.908 (0.589–1.402)   |                      |
| Widowed                                  | 1.006 (0.622–1.627)             | 1.031 (0.767–1.386)   |                      |
| Single                                   | 0.777 (0.620–0.973)             | 0.777 (0.471–1.282)   |                      |
| Occupation                               |                                 |                       |                      |
| Farmer, worker, and business             | 1.000                           | 1.000                 |                      |
| Leader, clerk, and technical             | 1.237 (1.070–1.430)             | 0.989 (0.782–1.251)   |                      |
| Others                                   | 0.979 (0.818–1.171)             | 0.782 (0.610–1.002)   |                      |
| Unemployment, student, retirement        | 1.155 (0.984–1.356)             | 1.074 (0.906–1.273)   |                      |
| Residence                                |                                 |                       |                      |
| Urban                                    | 1.000                           | 1.000                 |                      |
| Suburban                                 | 1.081 (0.963–1.214)             | 1.380 (1.195–1.593)   |                      |
| Outer suburbs                            | 1.186 (1.037–1.357)             | 1.825 (1.535–2.170)   |                      |
| Smoke                                    |                                 |                       |                      |
| Never smoke                              | 1.000                           | 1.000                 |                      |
| Smoke                                    | 1.270 (1.150–1.402)             | 1.283 (0.935–1.761)   |                      |
| Alcohol use                              |                                 |                       |                      |
| Never drink                              | 1.000                           | 1.000                 |                      |
| Drink                                    | 1.124 (1.009–1.252)             | 0.951 (0.687–1.317)   |                      |

Abbreviations: MetS=Metabolic syndrome; CIs=confidence intervals, BMI=body mass index.

*Adjusted for age, study cohort, residential area, sex, education levels, income levels, smoking, and drinking.

Increased compared to 2010 (24.5% and 11.0%, respectively) (10).

Prevalence of MetS varied significantly by gender. Males had a higher prevalence than females, which was different from the previous study. The prevalence was 27.0% among females and 19.2% among males in a
A significant increasing trend was observed in different age groups, as metabolic syndrome increased significantly with age (2). Developmental origins of health and disease well explained the origins of MetS in later life. Early-life malnutrition and later-life overnutrition were shown to be critical for metabolic disorders in adult life. Low birth weight, low socioeconomic status in early life increased the likelihood of adulthood metabolic disorders and chronic diseases.

Studies observed an association between a lower socioeconomic status and MetS prevalence; the ORs for MetS prevalence for residents in outer suburbs were higher than residents in urban. Dietary and lifestyle factors may contribute to the difference. Although it’s reported that the prevalence of MetS was higher in urban residents than in rural areas, the study was conducted on northwest Chinese adults who had different diets and lifestyles form Beijing adults (12). Smoking and drinking were related to higher risks of MetS, and the correlation between unhealthy lifestyle factors and lower socioeconomic status was also verified (8).

The study had several strengths. First, our study included a random representative and large sample of adults in Beijing. Second, all interviews were conducted face to face by trained health workers, and the anthropometric parameters were measured on-site, which allowed for rigorous quality control. Third, the sample constituted of both urban, suburban, and outer suburbs residents, which was representative of the diversity of environments in China. Fourth, this study used the new version of MetS criteria for Chinese adults, 2017 CDS, which would be more suitable since a previous study revealed that CDS definition was superior to The Adult Treatment Panel III of the National Cholesterol Education Program criteria and International Diabetes Federation when predicting factors and MetS among Chinese (9).

This study was subject to some limitations. First, this was a cross-sectional study, so the causal relation between factors and MetS risk could not be inferred. Second, lack of environmental exposure prevented us from exploring its effect on MetS.

In conclusion, MetS was prevalent among residents in Beijing. The findings suggested males, especially those living in the rural areas, who smoked, had lower education, higher BMI and were of older age were associated with an increased risk of MetS.

**Conflicts of Interest:** No conflicts of interest.

**Acknowledgments:** The local research teams from 16 districts of Beijing Center for Disease Prevention and Control, and the participants of the study.

**Funding:** Research Special Fund for Municipal Medical Public Welfare Institute (2017-BJYJ-15); National Natural Science Foundation of China (81373014); CNS-ZD Tizhi and Health Fund (CNS-ZD2020-115).

doi: 10.46234/ccdcw2022.138

* Corresponding authors: Gang Li, ligang@bjcdc.org; Bing Shao, shaobingch@sina.com; Le Zhang, zhangle@bjmu.edu.cn.

1. Institute of Reproductive and Child Health / Key Laboratory of Reproductive Health, National Health Commission of the People’s Republic of China, Peking University, Beijing, China; 2 Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China; 3 Department of Information and Statistics, Beijing Center for Disease Prevention and Control, Beijing, China; 4 Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, Beijing Center for Disease Prevention and Control, Beijing, China.

Joint first authors.

Submitted: November 16, 2021; Accepted: January 06, 2022

**REFERENCES**

1. Li CH, Lumey LH. Exposure to the Chinese famine of 1959-61 in early life and long-term health conditions: a systematic review and meta-analysis. Int J Epidemiol 2017;46(4):1157 – 70. http://dx.doi.org/10.1093/ije/dyx013.

2. Li R, Li WC, Lun ZJ, Zhang HP, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health 2016;16:296. http://dx.doi.org/10.1186/s12889-016-2870-y.

3. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33(2):351 – 75. http://dx.doi.org/10.1016/j.mec.2004.03.005.

4. Zhang WCB, Du J, Li H, Yang Y, Cai C, Gao Q, et al. Multiple-element exposure and metabolic syndrome in Chinese adults: a case-control study based on the Beijing population health cohort. Environ Int 2020;134:105959. http://dx.doi.org/10.1016/j.envint.2020.105959.

5. Chinese Diabetes Society. The guideline of type 2 diabetes prevention
6. Ma AJ, Fang K, Dong J, Dong Z. Prevalence and related factors of metabolic syndrome in Beijing, China (Year 2017). Obes Facts 2020;13(6):538-47. http://dx.doi.org/10.1159/000508842.

7. Wang ZW, Wang X, Li X, Chen Z, Zhao LC, Li Y, et al. Prevalence and trend of metabolic syndrome in middle-aged Chinese population. Chin J Epidemiol 2009;30(6):596-600. http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2009.06.015. (In Chinese).

8. Su YX, Lu YQ, Li WL, Xue MY, Chen C, Haireti M, et al. Prevalence and correlation of metabolic syndrome: a cross-sectional study of nearly 10 million multi-ethnic Chinese adults. Diabetes Metab Syndr Obes 2020;13:4869-83. http://dx.doi.org/10.2147/dmso.S278346.

9. Ning F, Ren J, Song X, Zhang D, Liu L, Zhang L, et al. Famine exposure in early life and risk of metabolic syndrome in adulthood: comparisons of different metabolic syndrome definitions. J Diabetes Res 2019;2019:7954856. http://dx.doi.org/10.1155/2019/7954856.

10. He YN, Zhao WH, Zhao LY, Yu DM, Zhang J, Yang XG, et al. Prevalence of metabolic syndrome in Chinese adults in 2010-2012. Chin J Epidemiol 2017;38(2):212-5. http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2017.02.015. (In Chinese).

11. Yi Y, An J. Sex differences in risk factors for metabolic syndrome in the Korean population. Int J Environ Res Public Health 2020;17(24):9513. http://dx.doi.org/10.3390/ijerph17249513.

12. Hailili G, Chen Z, Tian T, Fu WH, Pei HL, Mahan Y, et al. Dietary patterns and their associations with the metabolic syndrome and predicted 10-year risk of CVD in Northwest Chinese adults. Br J Nutr 2021;126(6):913–22. http://dx.doi.org/10.1017/s00071145200478x.
## Reported Cases and Deaths of National Notifiable Infectious Diseases — China, May 2022

| Diseases                                      | Cases | Deaths |
|-----------------------------------------------|-------|--------|
| Plague                                        | 0     | 0      |
| Cholera                                       | 0     | 0      |
| SARS-CoV                                      | 0     | 0      |
| Acquired immune deficiency syndrome*          | 4,490 | 1,466  |
| Hepatitis                                     | 125,758 | 38    |
| Hepatitis A                                   | 960   | 0      |
| Hepatitis B                                   | 102,912 | 25    |
| Hepatitis C                                   | 18,720 | 13    |
| Hepatitis D                                   | 21    | 0      |
| Hepatitis E                                   | 2,503 | 0      |
| Other hepatitis                               | 642   | 0      |
| Poliomyelitis                                 | 0     | 0      |
| Human infection with H5N1 virus               | 0     | 0      |
| Measles                                       | 110   | 0      |
| Epidemic hemorrhagic fever                    | 553   | 4      |
| Rabies                                        | 6     | 8      |
| Japanese encephalitis                         | 0     | 0      |
| Dengue                                        | 2     | 0      |
| Anthrax                                       | 19    | 0      |
| Dysentery                                     | 3,520 | 0      |
| Tuberculosis                                  | 63,590 | 316   |
| Typhoid fever and paratyphoid fever           | 566   | 0      |
| Meningococcal meningitis                      | 5     | 1      |
| Pertussis                                     | 3,991 | 1      |
| Diphtheria                                    | 0     | 0      |
| Neonatal tetanus                              | 1     | 0      |
| Scarlet fever                                 | 2,588 | 0      |
| Brucellosis                                   | 8,824 | 0      |
| Gonorrhea                                     | 8,395 | 0      |
| Syphilis                                      | 43,751 | 0    |
| Leptospirosis                                 | 10    | 0      |
| Schistosomiasis                               | 39    | 0      |
| Malaria                                       | 37    | 1      |
| Human infection with H7N9 virus               | 0     | 0      |
| COVID-19†                                     | 7,547 | 166    |
| Influenza                                     | 78,687 | 0    |
| Mumps                                         | 11,151 | 0    |
| Diseases                        | Cases | Deaths |
|--------------------------------|-------|--------|
| Rubella                        | 155   | 0      |
| Acute hemorrhagic conjunctivitis| 2,509 | 0      |
| Leprosy                        | 27    | 0      |
| Typhus                         | 144   | 0      |
| Kala azar                      | 35    | 0      |
| Echinococcosis                 | 235   | 0      |
| Filariasis                     | 0     | 0      |
| Infectious diarrhea            | 82,369| 1      |
| Hand, foot and mouth disease   | 70,042| 0      |
| **Total**                      | 519,156| 2,002 |

* The number of deaths of acquired immune deficiency syndrome (AIDS) is the number of all-cause deaths reported in the month by cumulative reported AIDS patients.
† The data were from the website of the National Health Commission of the People's Republic of China.
§ Infectious diarrhea excludes cholera, dysentery, typhoid fever and paratyphoid fever.

The number of cases and cause-specific deaths refer to data recorded in National Notifiable Disease Reporting System in China, which includes both clinically-diagnosed cases and laboratory-confirmed cases. Only reported cases of the 31 provincial-level administrative divisions in the mainland of China are included in the table, whereas data of Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan are not included. Monthly statistics are calculated without annual verification, which were usually conducted in February of the next year for de-duplication and verification of reported cases in annual statistics. Therefore, 12-month cases could not be added together directly to calculate the cumulative cases because the individual information might be verified via National Notifiable Disease Reporting System according to information verification or field investigations by local CDCs.

doi: 10.46234/ccdcw2022.127
